Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 6/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | IGF1R | P08069 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | FLT4 | P35916 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.31 |
| ▸ | TEK | Q02763 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20154999 | 0.91 | DGAT1 (0.39) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL30728208 | 0.86 | DGAT1 (0.38) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL27041306 | 0.86 | DGAT1 (0.38) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL23292002 | 0.85 | DGAT1 (0.40) | DGAT1MAPT | |
| SCHEMBL30903046 | 0.82 | DGAT1 (0.43) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL16611671 | 0.82 | DGAT1 (0.34) | DGAT1MAPT | |
| SCHEMBL112175 | 0.81 | DGAT1 (0.39) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL1076270 | 0.81 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL27041354 | 0.81 | DGAT1 (0.35) | DGAT1EGFRIGF1RSRCFLT4 | |
| SCHEMBL20155011 | 0.80 | DGAT1 (0.40) | DGAT1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720055-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4705292-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4558501-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | Arcus Biosciences, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2025-01-09 | — | — | US | disclosed |
| US-20240425497-A1 | Cbl-b Inhibitors and Methods of Use Thereof | ARCUS BIOSCIENCES, INC. (US) | 2024-12-26 | — | — | US | disclosed |
| WO-2024243502-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024233360-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024105563-A1 | SUBSTITUTED BICYCLIC PYRIDONE DERIVATIVES | PFIZER INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-115667237-A | Novel heterocyclic compounds as BET inhibitors | 成都苑东生物制药股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | DGAT1 2448/4885EGFR 4532/4885IGF1R 1827/4885 |
| US-20240425497-A1 | Cbl-b Inhibitors and Methods of Use Thereof | CBLB, CBL, CBLC | DGAT1 4282/4885EGFR 218/4885IGF1R 622/4885 |
| US-20260028336-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | DGAT1 4344/4885EGFR 67/4885IGF1R 100/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | DGAT1 2448/4885EGFR 4532/4885IGF1R 1827/4885 |
| US-20250011318-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | DGAT1 4368/4885EGFR 238/4885IGF1R 488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.